Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 11, 2002 - Issue 1
Submit an article Journal homepage
85
Views
14
CrossRef citations to date
0
Altmetric
Miscellaneous

Clinical developments for treating ARDS

Greg Martin Division of Pulmonary and Critical Care Medicine, Emory University, 550 Peachtree Street, NE, Atlanta, GA 30308, USA
&
Stephanie Eaton Division of Pulmonary and Critical Care Medicine, Emory University, 550 Peachtree Street, NE, Atlanta, GA 30308, USA
Pages 37-48 | Published online: 24 Feb 2005

Bibliography

  • MURRAY JF, MATTHAY MA, LUCE JM et al.: An expanded definition of the adult respiratory distress syndrome. Am. Rev Rap*: Dis. (1988) 138:720–723.
  • BERNARD GR, ARTIGAS A, BRIGHAM KL: The American-European Consensus Conference on ARDS. Definition, mechanisms, relevant outcomes, and clinical trial coordination. Am. J. Respir. Grit. Care Med. (1994) 149(3 Pt 1):818–824.
  • ••In this article, a consensus definition forARDS was presented. This definition has since been used to define patients for inclusion in many therapeutic ARDS trials.
  • LUHR R, ANTONSEN K, KARLSSON M et al.: Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. Am. J. Rap*: Grit. Care Med. (1995) 159:1849–1861.
  • NIH grant 5P50HL030542-180006. Epidemiology and inflammatory responses in acute lung injury. Principal investigator: Leonard D. Hudson, M.D. University of Washington, Seattle, WA, USA.
  • MILBERG JA, DAVIS DR, STEINBERG KP, HUDSON LD: Improved survival of patients with acute respiratory distress syndrome (ARDS). JAMA (1995) 273:306–309.
  • DOYLE IR. BERSTEN AD. NICHOLAS TE: Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure. Am. J. Rap*: Grit. Care Med. (1997) 156(4 Pt 1):1217–1229.
  • LEWIS JF, JOBE AH: Surfactant and the adult respiratory distress syndrome. Am. Rap*: D AK (1993) 147:218–233.
  • HOLM BA, MATALON S: Role of pulmonary surfactant in the development and treatment of adult respiratory distress syndrome. Arrestb. Arialg. (1989) 69:805–818.
  • PISON U, OBERTAKE U, BRAND M et al.: Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure. J. Trauma (1990) 30:19–26.
  • GREGORY TJ, LONGMORE WJ, MOXLEY MA et al.: Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J. Gun. Invest. (1991) 99:1976–1981.
  • WIS WELL TE, SMITH RM, KATZ LB et al.: Bronchopulmonary segmental lavage with Surfaxin (KL4-Surfactant) for acute respiratory distress. Am. J. Rap*: Grit. Care Med. 1999; 160(4):1188–1195.
  • WEG JG, BALK RA, THARRATT RS et al: Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA (1994) 272 (18) :1433–1438.
  • ANZUETO A, BAUGHMAN RP, GUNTUPALLI la et al.: Aerosolized surfactant in adults withsepsis-induced adult respiratory distress syndrome. New Engl. J. Med. (1996) 334(22):1417–1421.
  • •This article reports that the Exosurf formulation of surfactant did not alter outcome in ARDS.
  • GREGORY TJ, STEINBERG KP, SPRAGG R et al.: Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am. J. Respir. Grit. Care Med (1997) 155(4):1309–15.
  • SATOH D, MATSUKAWA S, SAISHU T etal.: Effect of surfactant on respiratory failure associated with thoracic aneurysm surgery. Grit. Care Med (1998) 26(10):1660–1662.
  • DELLINGER FP, ZIMMERMAN JL, TAYLOR RW et al.: Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: Results of a randomized Phase II trial. Grit. Care Med. (1998) 26:15–23.
  • •This article reports results from a multicentre trial evaluating the safety and dose-response of iN0 in ARDS.
  • LUNDIN S, MANG H, SMITHIES M, STENQVIST 0, FROSTELL C: Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. Irm Care. Med. (1999) 25:911–919.
  • KLEINSASSER A, LOECKINGER A, HOERMANN C et al.: Sildenafil modulates hemodynamics and pulmonary gas exchange. Am. J. Respic Grit. Care Med. (2001) 163(2)339–43.
  • JACOBS BR, BRILLI RJ, BALLARD ET, PASSERINI DJ, SMITH DJ: Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury. Am. J. Respir. Grit. Care Med. (1998) 158(5):1536–42.
  • CLARK LC JR, GOLLAN F: Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science (1966) 20:1755–1756.
  • KYLSTRA JA, TISSING MO, VAN DER MAEN A: Of mice as fish. Trans. ASAIO. (1962) 8:378–383.
  • CALDERWOOD HW, MODELL JH, RUIZ BC, BROGDON JE, HOOD CI: Pulmonary lavage with liquid fluorocarbon in a model of pulmonary edema. Anesthesiology (1973) 38:141–144.
  • MODELL JH, NEWBY EJ, RUIZ BC: Long-term survival of dogs after breathing oxygenated fluorocarbon liquid. Fed. Proc. (1979) 29:1731–1736.
  • TUTUNCU AS, FAITHFUL NS, AKPIR K, LACHMANN B: Improvement of gas exchange dose dependently by intratracheal perfluorocarbon administration in adult animals with acute respiratory failure. Clin. Intensive Care (1992) 3 (Suppl.):72.
  • RICHMAN PS, WOLFSON MR, SHAFFER TH: Lung lavage with oxygenated perfluorochemical liquid in acute lung injury. Grit. Care Med. (1993) 20:768–774.
  • NESTI FD, FUHRMAN BP, STEINHORN DM etal.: Perfluorocarbon-associated gas exchange in gastric aspiration. Grit. Care Med. (1994) 22(9):1445–1452.
  • HIRSCHL RB, TOOLEY R, PARENT A, JOHNSON K, BARTLET RH: Evaluation of gas exchange, pulmonary compliance, and lung injury during total and partial liquid ventilation in the acute respiratory distress syndrome. Grit. Care Med. (1996) 24(6):1001–1008.
  • LOWE C, SHAFFER T: Pulmonary vascularresistance in the fluorocarbon-filled lung. J. Appl. Physiol. (1986) 60:154–159.
  • HIRSCHL RB, CONRAD S, KAISER R, ZWISCHENBERGER JB, BARTLETT RH, BOOTH E CARDENAS V: Partial liquid ventilation in adult patients with ARDS: a multicenter Phase I-II trial. Ann. Surg. (1998) 228(5):692–700.
  • •This is the first study of partial liquid ventilation in adults with ARDS who are not also receiving extracorporeal membrane oxygenation.
  • HIRSCHL RB, PRANIKOFF T, WISE, C: Initial experience with partial liquid ventilation in adult patients with the acute respiratory distress syndrome. JAMA (1996) 275:383–389.
  • GUNTHER A, WALMRATH D, GRIMMINGER F, WERNER S: Pathophysiology of acute lung injury. In: Seminars in Respiratory and Critical Care Medicine. Hall JB and Schmidt GA (Eds.), Thieme Medical Publishers (2001) 22(3):247–258.
  • CHOPRA J, BEBSTER RO: PGE1 inhibits neutrophil adherence and neutrophil-mediated injury to cultured endothelial cells. Am. Rev Respir. Dis. (1988) 138:915–920.
  • SINZINGER H, O'GRADY J FITSCHA P et al.: Comparable effect of prostaglandin El in decreasing in vivo platelet deposition on human lesion sites after intravenous and intraarterial application. Thromb. Res. (1988) 50:749–755.
  • PRIEBE HJ:Efficacy of vasodilator therapyin a canine model of acute pulmonary hypertension. Am. J. Physiol. (1988) 255:H1232–H1239.
  • EIERMAN DE YAGAMI M, ERMA SM et al.: Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia. Proc. Natl. Acad. Sci. USA (1995) 92:2815–2819.
  • ROSSETTI RG, BRATHWAITE K, ZURIER RB: Suppression of acute inflammation with liposome associated PGE1. Prostaglandins (1994) 48:187–195.
  • LEFF JA, BAER JW, KIRKMAN JM et al.: Liposome-entrapped PGE1 posttreatment decreases IL-1-induced neutrophil accumulation and lung leak in rats. J. Appi Phsiol. (1994) 76:151–157.
  • ABRAHAM E, PARK YC, CONINGTON P, CONRAD SA, SCHWARTZ M: Liposomal prostaglandin El in acute respiratory distress syndrome: A placebo-controlled, randomized, double-blind, multicenter clinical trial. Grit. Care Med. (1996) 24(1):10–15.
  • ABRAHAM E, BAUGHMAN R, FLETCHER E et al.: Liposomal prostaglandin El (TLC C-53) in acute respiratory distress syndrome: A controlled, randomized, double-blind, multicenter clinical trial. Grit. Care Med. (1999) 27(8):1478–1485.
  • VINCENT J-L, RAINER B, SANTMAN F: A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin El (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med. (2001): Published online.
  • •This randomised controlled clinical trial demonstrated that despite earlier favourable trials, liposomal PGE1 does not alter long-term outcomes in ARDS.
  • EISEMAN E, FINNEY R, CAI F et al.: Lisofylline inhibits the induction of stress activated protein kinase (SAPK) and pro-inflammatory cytokines by taxol, LPS, IL-1 and TNF-alpha. Blood (1995) 86 (10 Suppl. 1):abstr. 2755.
  • HASEGAWA N, OKAY, NAKAYAMA Met al.: The effects of post-treatment with lisofylline, a phosphatidic acid generation inhibitor, on sepsis-induced acute lung injury in pigs. Am. J. Respir: Grit. Cam (1997) 155(3):928–936.
  • HYBERTSON BM, BURSTEN SL, LEFF JA et al.: Lisofylline prevents leak, but not neutrophil accumulation, in lungs or rats given IL-1 intratracheally. J. App. Physiol. (1997) 82(2):226–232.
  • CELL THERAPEUTICS INC: Cell Therapeutics stops enrollment in Phase II/III trial of lisofylline for acute lung injury. Press Release (1999).
  • BERNARD GR, WHEELER AP, NAUM CC et al.: A placebo controlled, randomized trial of IL-10 in acute lung injury. Chest (1999) 116(4): 260S.
  • PRESCOTT SM, MCINTYRE TM, ZIMMERMAN GA: Platelet-activating factor: a phospholipid mediator inflammation. In: Inflammation Basic Principles and Clinical Correlates (Third ed). Gallin JI, Snyderman R, (Ed.), Lippincott Williams & Wilkins, Philadelphia, USA (1999): 387–396.
  • RABINOVICI R, ESSER KM, LYSKO PG et al.: Priming by platelet-activating factor of endotoxin-induced lung injury and cardiovascular shock. Circ. Res. (1991) 69:12–25.
  • MATSUMOTO K, TAM F, KONDOH Y, TONIGUCHI J, TAKAGI K: Platelet-activating factor in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Clin. Exp. Pharmacol. Physiol. (1992) 19:509–515.
  • NAGASE T, ISHII S, KUME K et al.: Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice. J Clin. Invest. (1999) 104(8):1071–1076.
  • RABINOVICI R, SOFRONSKI MD, RENZ JF et al.: Platelet activating factor mediates interleukin-2-induced lung injury in the rat. J. Chia. Invest. (1992) 89:1669–1673.
  • HANG S-W, FEDDERSEN CO, HENSON PM, VOELKEL NF: Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J. Clin. Invest. (1987) 79:149–1509.
  • FIFTH WORLD CONGRESS MUNICH, GERMANY: Trauma, shock,inflammation and sepsis: pathophysiology, immune consequences and therapy. IDdb Meeting Report (2000) Feb 29 - Mar 4.
  • GALLOWAY SW, KINGSNORTH AN: Acute lung injury in the microembolic model of acute pancreatitis. Digestion (1994) 55(5):300–301.
  • ZIMMERMAN JL, DELLINGER FP, STRAUBE RC, LEVIN JL: Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Grit. Care Med. (2000) 28(9):3149–3154.
  • •This phase I trial of TP-10 demonstrated in-vivo activity and a good safety profile.
  • T CELL SCIENCES INC: T Cell Sciences Completes Patient Enrollment for Phase I/II Trial of TP10 for Reperfusion Injury following Lung Transplantation. Press Release (1997).
  • AVANT IMMUNOTHERAPEUTICS INC: AVANT's second generation complement inhibitor targets sites of injury increasing its anti-inflammatory effects. Press Release (1999).
  • GLAUSER FL, FAIRMAN RP: The uncertain role of the neutrophil in increased permeability pulmonary edema. Chest (1985) 88:601–607.
  • IDELL S, KUCICH U, FEIN A et al: Neutrophil elastase-releasing factors in bronchoalveolar lavage from patients with adult respiratory distress syndrome. Am. Rev Rap*: Dis. (1985) 132:1098–1105.
  • •Neutrophil elastase-releasing factors were found to be significantly elevated in patients with ARDS compared to patients with sarcoidosis, pulmonary fibrosis and normal controls.
  • LEE C, FEIN A, LIPPMANN M et al.: Elastolytic activity in pulmonary lavage fluid from patients with adult respiratory-distress syndrome. N Engl. J Med. (1981) 304:192–196.
  • STOKKE T. BURCHARDI H. HENSEL I. KOSTERING H. KATHNER T. RAHLF G: Continuous intravenous infusion of elastase in normal and agranulocytic minipigs--effects on the lungs and the blood coagulation system. Resuscitation (1998) 14(1-2):61–79.
  • MURAKAMI K, OKAJIMA K, UCHIBA M et al: Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes. Grit. Care Med (1996) 24:1047–1053.
  • •A synthetic protease inhibitor was found to attenuate endotoxin-induced pulmonary vascular injury in a rat model.
  • ZAPOL WM, JONES R: Vascular components of ARDS: clinical pulmonary hemodynamics and morphology. Am. Rev Rap*: Dis. (1987) 136:471–474.
  • LEEMAN M: The pulmonary circulation in acute lung injury: A review of some recent advances. Int. Care Med. (1991) 17:254–260.
  • MEYRICK B. Pathology of the adult respiratory distress syndrome. Grit. Care OM (1986) 2(3): 405–428.
  • REYES A, ROCA J, RODRIGUEz-ROISIN R, TORRES A, USSETTI E WAGNER PD: Effect of almitrine on ventilation-perfusion distribution in adult respiratory distress syndrome. Am. Rev Respir: Dis.(1988) 137:1062–1067.
  • WYSOCKI M, DELCAUX C, ROUPLE E etal.: Additive effect on gas exchange of inhaled nitric oxide and intravenous almitrine bismesylate in the adult respiratory distress syndrome. Int. Care. Med. (1994) 20:54–259.
  • LU Q, MOURGEON E, LAW-KOUNE JD et al: Dose-response of inhaled NO with and without intravenous almitrine in adult respiratory distress syndrome. Anesthesiology (1995) 83:929–943.
  • GALLART L, QIN L, PUYBASSET L, UMAMAHESWARA ROA GS, CORIAT E ROUBY J-J: Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome. Am. fRespir: Crit. Care Med. (1998) 158:1770–1777.
  • •This article reports a dose-ranging prospective trial of iN0 and iv. almiltrine in ARDS.
  • DOERING, EB, HANSON CW, REILY DJ, MARSHALL C, MARSHALL BE: Improvement in oxygenation by phenylephrine and nitric oxide in patients with adult respiratory distress syndrome. Anesthesiology (1997) 87(1)18–25.
  • WALMRATH D, SCHNEIDER T, PILCH J, GRIMMINGER E SEEGER W: Aerosolized prostacyclin in adult respiratory distress syndrome. Lancet (1993) 342(8877):961–962.
  • VAN HEERDEN PV, BARDEN A, MICHALOPOULOS N, BULSARA MK, ROBERTS BL: Dose-Response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest (2000) 117(3):819–827.
  • •This article reports a dose-ranging prospective trial of aerosolised prostacyclin in nine patients with severe ARDS.
  • DOMENIGHETTI G, STRICKER H, WALDISPUEHL B: Nebulized prostayclin (PGI2) in acute respiratory distress syndrome: Impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Crit. Care Med (2001) 29(1):57–62.
  • •Computed tomography images of prone and supine patients with ARDS are described.
  • GATTINONI L, PELOSI E VITALE G et al.: Body position changes redistribute lung computed tomographic density in patients with acute respiratory failure. Anaesthesiology (1991) 74: 15–23.
  • TANABE E, UEDA M, ENDO M KIAJIMA M: Effect of acute lung injury and coexisting disorders on plasma concentrations of atrial natriuretic peptide. Crit. Care Med. (1994) 22(11):1762–1768.
  • TANABE E, UEDA M, ENDO M, KITAJIMA M: The effect of atrial natriuretic peptide on pulmonary acid injury in a pig model. Am. J Rap*: Crit. Care Med. (1996) 154(5):1351–1356.
  • IMAMURA T, OHNUM N, IAZ C et al:Protective effect of alpha-human atrial natriuretic polypeptide (alpha-hANP) on chemical-induced pulmonary edema. Life Sciences (1988) 42(4):403–414.
  • MITAKA C, HIRATA Y, NAGURA T, TSUNODA Y, AMAHA K: Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury. Chest (1998) 114:223–228.
  • FUCHS-BUDER T, DE MOERLOOSE P, RICOU B et al: Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome. Am. Respir: Grit. Care Med. (1996) 153:163–167.
  • BACHOFEN M, WEIBEL ER: Structural alterations of lung parenchyma in the adult respiratory distress syndrome. OM. Chest Med. (1982) 3:35–56.
  • HARTMAN DL, BERNARD GR, HELTERBRAND JD, YAN SB, FISHER CJ: Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis. Intensive Care Med. (1998) 24 (Suppl. 1):577.
  • ESMON CR: Introduction: Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood (2000) 95:1113–1116.
  • BERNARD GR, VINCENT L-L, LTERR P-F et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl. j Med. (2001) 344:699–709.
  • ••This article reports a significant survivalbenefit for patients wit severe sepsis treated with activated protein C. This may have a significant impact of ARDS as sepsis is the most common risk for ARDS.
  • WELTY-WOLF KE, CARRAWAY MS, NUANG YC-T etal.: Blockade of extrinsic coagulation decreases lung injury in baboons with gram-negative sepsis. Am. I Respic Crit. Care Med. (2000) 161:A517.
  • BIO-TECHNOLOGY GENERAL CORP: Annual Report. (1994).
  • DIDLAKE R, KIRCHNER KA, LEWIN J, BOWER HD, MARKAV A: Protection from ischemic renal injury by fructose-1,6-diphosphate infusion in the rat. Circulatory Shock (1985) 16(2):205–212.
  • JANZ TG, LEASURE J, OLSEN JE: The effects of fructose-1, 6-diphosphate on myocardial damage in acute coronary artery occlusion. Resuscitation (1991) 22:45–54.
  • BERNARD GR, LUCE JM, SPRUNG CL et al.: High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl. Merl (1987) 317:1565–1570.
  • SPRUNG CL, CARALIS PV, MARCIAL EH etal.: The effects of high-dose corticosteroids in patients with septic shock: a prospective, controlled study. N Engl. Med. (1984) 311:1137–1143.
  • MEDURI GU, HEADLEY AS, GOLDEN E: Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA (1998) 280:159–165.
  • •This article reports a dramatic survival benefit for unresolving ARDS patients treated with corticosteroids. This small trial has prompted a larger multicentre controlled study in order to more clearly determine the efficacy of corticosteroids in ARDS.
  • BERNARD G, WHEELER A, ARONS Met al.: A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest (1997) 112:164–172.
  • •This article reports that glutathione stores can be repleted using N-acetylcysteine or procysteine and may decrease the duration of acute lung injury.
  • STEINBERG S, DEHRING D, MARTIN D et al.: Amelioration of pulmonary pathophysiology of adult respiratory distress syndrome by sulindac, a cyclo-oxygenase inhibitor. j Trauma (1987) 67:1103–1110.
  • BORG T, GERDIN B, MODIG J: Prophylactic and delayed treatment with indomethacin in a porcine model of early adult respiratory distress syndrome induced by endotoxaemia. Acta. Anaesthesia. Land. (1986) 30:47–59.
  • BERNARD G, WHEELER A, RUSSELL J et al.: The effects of ibuprofen on the physiology and survival of patients with sepsis. N. Engl. J. Med. (1997) 336:912–918.
  • ARONS MM, WHEELER AE BERNARD GR etal.: Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Grit. Care Med. (1999) 27(4):699–707.
  • ALSOUS E KHAMIEES M, DEGIROLAMO A et al.: Negative fluid balance predicts survival in patients with septic shock: a retrospective pilot study. Chest (2000) 117(6):1749–1754.
  • SIMMONS RS, BERDINE GG, SEIDENFELD JJ et al.: Fluid balance and the adult respiratory distress syndrome. Am. Rev Respir. Dis. (1987) 135:924–929.
  • HUMPHREY H, HALL J, SZNAJDER I, SILVERSTEIN M, WOOD L: Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure. Chest (1990) 97(5):1176–1180.
  • MANGIALARDI RJ, MARTIN GS, BERNARD GR etal.: Hypoproteinemia predicts ARDS development, weight gain, and death in patients with sepsis. Grit. Care Med. (2000) 28(9):3137–3145.
  • •This article describes a retrospective analysis of data from patients with severe sepsis showing that hyypoproteinemia correlated with development of ARDS and respiratory mortality.
  • MITCHELL JP, SCHULLER D, CALANDRINO FS, SCHUSTER DP: Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. Am. Rev Respir: Dis. (1992) 145:990–998.
  • MARTIN GS, MANGIALARDI RJ, WHEELER AE BERNARD GR: Albumin and diuretics in ARDS [abstract]. Am. Respir. Grit. Care Med. (1999) 159(3):A376.
  • GADEK JE, DEM1CHELE SJ, KARLSTAD: Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Grit. Care Med. (1999) 27(8):1409–1420.
  • •This article reports results from a randomised controlled trial of anti-oxidant enriched enteral feeding in patients with ARDS.
  • ACUTE RESPIRATORY DISTRESS SYNDROME NETWORK INVESTIGATORS: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl. Med. (2000) 342:1301–1308.
  • ••This landmark study reports a survivalimprovement in ARDS using a protective lung ventilation strategy. This strategy is becoming the standard of care for ARDS patients.
  • AMATO MB, BARBAS CS, MEDEIROS DM et al.: Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl. j Med. (1998) 338(6):347–354.
  • STEWART TE, MEADE MO, COOK DJ et al.: Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome. N Engl. J. Med. (1998) 338(6):355–361.
  • BROCHARD L, ROUDOT-THORAVAL E ROUPIE E et al: Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. Am. Rap*: Grit. Care Med. (1998) 158(6):1831–1838.
  • MEHTA S, LAPINSKY SE, HALLETT DC et al.: Prospective trial of high-frequency oscillation in adults with acute respiratory distress syndrome. Grit. Care Med. (2001) 29(7):1360–1369.
  • GATTINONI L, TOGNONI G, PESENTI A etal.: Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl. j Med. (2001) 345(8):568–573.
  • •This article reports results from a multicentre trial demonstrating that prone positioning may improve oxygenation but does not improve mortality in ARDS.
  • CHOU NK, CHEN YS, KO WJ et al: Application of extracorporeal membrane oxygenation in adult burn patients. Artificial Organs (2001) 25(8):622–626.
  • LINDEN V, PALMER K, REINHARD J et al.: High survival in adult patients with acute respiratory distress syndrome treated by extracorporeal membrane oxygenation, minimal sedation, and pressure supported ventilation. Intensive Care Med. (2000) 26(11):1630–1637.

Websites

  • http://www.chestnet.org/CHEST/ 192001/ program/presentations/plenary33.htm. ANNANE D: Plenary presentation, Chest 2001, Philadelphia, PA USA.(2001).
  • http://www.cesar-trial.org.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.